Furthermore, given the binding properties of PD-L1 and PD-L2, the significant upregulation of PD-L2 by tumor cells could compensate for the inhibition of PD-1 signaling when PD-L1 inhibitors are solely used for therapy. This evidence concerns the gene PDCD1LG2 and neoplasm.